Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBOE-Mayo
NCT07213466Phase 4Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide, naltrexone + bupropion, phentermine + topiramate in obesity, sponsored by Mayo Clinic. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07213466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213466.